Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado-Miranda, Alberto, Lara-Medina, Fernando Ulises, Muñoz-Montaño, Wendy R., Zinser-Sierra, Juan W., Galeana, Paula Anel Cabrera, Garza, Cynthia Villarreal, Sanchez Benitez, Daniel, Limón Rodríguez, Jesús Alberto, Arce Salinas, Claudia Haydee, Guijosa, Alberto, Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377785/
https://www.ncbi.nlm.nih.gov/pubmed/37504314
http://dx.doi.org/10.3390/curroncol30070454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377785/
https://www.ncbi.nlm.nih.gov/pubmed/37504314
http://dx.doi.org/10.3390/curroncol30070454

Ejemplares similares